Klor-con and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Klor-con (potassium chloride), especially for people who are female, 60+ old, also take Ibrance, and have Breast cancer female.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Klor-con. It is created by eHealthMe based on reports of 27,036 people who have side effects when taking Klor-con from the FDA, and is updated regularly.

What is Klor-con?

Klor-con has active ingredients of potassium chloride. It is often used in hypokalemia. eHealthMe is studying from 27,547 Klor-con users. Check the latest studies of Klor-con.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 535 drugs and 467 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Jul, 09, 2026

27,036 people reported to have side effects when taking Klor-con.
Among them, 11 people (0.04%) have Second primary malignancy.

Could Klor-con cause Second primary malignancy?

Among these 11 people:

What is the gender of people who have Second primary malignancy when taking Klor-con? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Second primary malignancy when taking Klor-con? *

What are other drugs people take besides Klor-con? *

What are other side effects people have besides Second primary malignancy? *

Pain: 8 people, 72.73%
Fatigue (feeling of tiredness): 8 people, 72.73%
Dizziness: 7 people, 63.64%
Chest Pain: 7 people, 63.64%
Diarrhea: 6 people, 54.55%
Weakness: 6 people, 54.55%
Bone Pain: 6 people, 54.55%
Dyspnea (difficult or laboured breathing): 5 people, 45.45%
Insomnia (sleeplessness): 5 people, 45.45%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 4 people, 36.36%

What are the existing conditions these people have? *

Breast Cancer Female: 4 people, 36.36%
Multiple Myeloma (cancer of the plasma cells): 2 people, 18.18%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 18.18%
Breast Cancer: 2 people, 18.18%
Type 2 Diabetes: 1 person, 9.09%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 9.09%
Procedural Pain: 1 person, 9.09%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 1 person, 9.09%
Depression: 1 person, 9.09%
Breast Cancer Metastatic: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Klor-con and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Klor-con:

Klor-con (27,547 reports)

Browse all side effects of Klor-con:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (535 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (467 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on potassium chloride (the active ingredients of Klor-con) and Klor-con (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.